Cargando…

Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma

SIMPLE SUMMARY: Proteinuria is a common adverse event of systemic therapy for hepatocellular carcinoma (HCC); however, its effect on clinical outcomes is not well understood. A retrospective analysis of 321 patients with unresectable HCC who received systemic therapy as first-line treatment was perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Kazuyuki, Imai, Norihiro, Yamamoto, Takafumi, Yokoyama, Shinya, Yamamoto, Kenta, Ito, Takanori, Ishizu, Yoji, Honda, Takashi, Kuzuya, Teiji, Ishigami, Masatoshi, Kawashima, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216745/
https://www.ncbi.nlm.nih.gov/pubmed/37345189
http://dx.doi.org/10.3390/cancers15102853
_version_ 1785048371765968896
author Mizuno, Kazuyuki
Imai, Norihiro
Yamamoto, Takafumi
Yokoyama, Shinya
Yamamoto, Kenta
Ito, Takanori
Ishizu, Yoji
Honda, Takashi
Kuzuya, Teiji
Ishigami, Masatoshi
Kawashima, Hiroki
author_facet Mizuno, Kazuyuki
Imai, Norihiro
Yamamoto, Takafumi
Yokoyama, Shinya
Yamamoto, Kenta
Ito, Takanori
Ishizu, Yoji
Honda, Takashi
Kuzuya, Teiji
Ishigami, Masatoshi
Kawashima, Hiroki
author_sort Mizuno, Kazuyuki
collection PubMed
description SIMPLE SUMMARY: Proteinuria is a common adverse event of systemic therapy for hepatocellular carcinoma (HCC); however, its effect on clinical outcomes is not well understood. A retrospective analysis of 321 patients with unresectable HCC who received systemic therapy as first-line treatment was performed to assess the impact of pretreatment proteinuria on treatment response. Patients without pretreatment proteinuria who received lenvatinib or atezolizumab plus bevacizumab had longer overall survival, but those treated with sorafenib did not. Additionally, a quantitative analysis of 111 patients treated with lenvatinib or atezolizumab plus bevacizumab revealed that the severity of proteinuria was an independent predictor of prognosis, along with liver function. Therefore, pretreatment proteinuria may predict a poorer prognosis in patients with unresectable HCC treated with lenvatinib or atezolizumab plus bevacizumab but not in those treated with sorafenib. ABSTRACT: Background: Proteinuria is a common adverse event in systemic therapy for hepatocellular carcinoma (HCC). However, whether the presence of pretreatment proteinuria affects the clinical course is still unclear. Method: From 2011 to 2022, 321 patients with unresectable HCC who were treated with systemic therapy as first-line treatment were enrolled in this study. We retrospectively analyzed the presence of pretreatment proteinuria and the treatment course of systemic therapy. Results: In the cohort, 190 patients were tested for proteinuria qualitatively within 3 months before systemic therapy; 75 were treated with sorafenib, 72 were treated with lenvatinib, and 43 were treated with atezolizumab plus bevacizumab. Overall survival tended to be longer for patients treated with lenvatinib and significantly longer with atezolizumab plus bevacizumab in patients without pretreatment proteinuria but not for those treated with sorafenib. Further analysis was performed in 111 patients treated with lenvatinib or atezolizumab plus bevacizumab who had proteinuria measured quantitatively. Multivariate analysis including proteinuria, liver function, and HCC stage revealed that the severity of proteinuria was an independent predictor of prognosis. Conclusion: Pretreatment proteinuria predicts a poorer prognosis in patients with unresectable HCC treated with lenvatinib or atezolizumab plus bevacizumab but not in those treated with sorafenib.
format Online
Article
Text
id pubmed-10216745
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102167452023-05-27 Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma Mizuno, Kazuyuki Imai, Norihiro Yamamoto, Takafumi Yokoyama, Shinya Yamamoto, Kenta Ito, Takanori Ishizu, Yoji Honda, Takashi Kuzuya, Teiji Ishigami, Masatoshi Kawashima, Hiroki Cancers (Basel) Article SIMPLE SUMMARY: Proteinuria is a common adverse event of systemic therapy for hepatocellular carcinoma (HCC); however, its effect on clinical outcomes is not well understood. A retrospective analysis of 321 patients with unresectable HCC who received systemic therapy as first-line treatment was performed to assess the impact of pretreatment proteinuria on treatment response. Patients without pretreatment proteinuria who received lenvatinib or atezolizumab plus bevacizumab had longer overall survival, but those treated with sorafenib did not. Additionally, a quantitative analysis of 111 patients treated with lenvatinib or atezolizumab plus bevacizumab revealed that the severity of proteinuria was an independent predictor of prognosis, along with liver function. Therefore, pretreatment proteinuria may predict a poorer prognosis in patients with unresectable HCC treated with lenvatinib or atezolizumab plus bevacizumab but not in those treated with sorafenib. ABSTRACT: Background: Proteinuria is a common adverse event in systemic therapy for hepatocellular carcinoma (HCC). However, whether the presence of pretreatment proteinuria affects the clinical course is still unclear. Method: From 2011 to 2022, 321 patients with unresectable HCC who were treated with systemic therapy as first-line treatment were enrolled in this study. We retrospectively analyzed the presence of pretreatment proteinuria and the treatment course of systemic therapy. Results: In the cohort, 190 patients were tested for proteinuria qualitatively within 3 months before systemic therapy; 75 were treated with sorafenib, 72 were treated with lenvatinib, and 43 were treated with atezolizumab plus bevacizumab. Overall survival tended to be longer for patients treated with lenvatinib and significantly longer with atezolizumab plus bevacizumab in patients without pretreatment proteinuria but not for those treated with sorafenib. Further analysis was performed in 111 patients treated with lenvatinib or atezolizumab plus bevacizumab who had proteinuria measured quantitatively. Multivariate analysis including proteinuria, liver function, and HCC stage revealed that the severity of proteinuria was an independent predictor of prognosis. Conclusion: Pretreatment proteinuria predicts a poorer prognosis in patients with unresectable HCC treated with lenvatinib or atezolizumab plus bevacizumab but not in those treated with sorafenib. MDPI 2023-05-21 /pmc/articles/PMC10216745/ /pubmed/37345189 http://dx.doi.org/10.3390/cancers15102853 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mizuno, Kazuyuki
Imai, Norihiro
Yamamoto, Takafumi
Yokoyama, Shinya
Yamamoto, Kenta
Ito, Takanori
Ishizu, Yoji
Honda, Takashi
Kuzuya, Teiji
Ishigami, Masatoshi
Kawashima, Hiroki
Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
title Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
title_full Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
title_fullStr Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
title_full_unstemmed Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
title_short Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
title_sort pretreatment proteinuria predicts the prognosis of patients receiving systemic therapy for unresectable hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216745/
https://www.ncbi.nlm.nih.gov/pubmed/37345189
http://dx.doi.org/10.3390/cancers15102853
work_keys_str_mv AT mizunokazuyuki pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT imainorihiro pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT yamamototakafumi pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT yokoyamashinya pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT yamamotokenta pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT itotakanori pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT ishizuyoji pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT hondatakashi pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT kuzuyateiji pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT ishigamimasatoshi pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma
AT kawashimahiroki pretreatmentproteinuriapredictstheprognosisofpatientsreceivingsystemictherapyforunresectablehepatocellularcarcinoma